Bivalirudin

Bivalirudin is a synthetic 20-amino acid bivalent direct thrombin inhibitor and structural analogue of hirudin, the anticoagulant protein of the medicinal leech Hirudo medicinalis. Its molecular weight is approximately 2,180 daltons.

The molecule is composed of three functional domains. At the N-terminus is the tetrapeptide D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl (D-Phe-Pro-Arg-Pro), which occupies the active catalytic (serine) site of thrombin and blocks its proteolytic activity. At the C-terminus is a 12-amino acid sequence (QGDFEEIPEEYL) derived from the C-terminal fibrinogen-recognition domain of hirudin isoform 1, which binds the anion-binding exosite 1 of thrombin. These two domains are joined by a tetra-glycine spacer (Gly-Gly-Gly-Gly) that provides conformational flexibility.

This bivalent architecture confers several pharmacological advantages over indirect anticoagulants:

• Simultaneous occupation of both the active catalytic site and exosite 1 produces potent, selective thrombin inhibition without requiring antithrombin or any other plasma cofactor, in contrast to heparin and low-molecular-weight heparins.

• Unlike heparin, bivalirudin can penetrate and inhibit thrombin that is already bound within a developing clot (clot-bound thrombin), which retains catalytic activity and can perpetuate coagulation amplification through positive feedback loops.

• The inhibition is reversible: thrombin itself slowly cleaves the Arg3-Pro4 bond within the N-terminal active-site binding domain, partially restoring thrombin catalytic activity over time. This self-attenuating mechanism contributes to the drug's predictable pharmacodynamics.

By blocking thrombin's active site and exosite 1, bivalirudin prevents the conversion of fibrinogen to fibrin, the activation of coagulation factors V, VIII, and XIII, and thrombin-mediated platelet aggregation.

In patients with normal renal function, bivalirudin has a plasma half-life of approximately 25 minutes. Clearance occurs via a combination of proteolytic cleavage by circulating and tissue proteases (approximately 80%) and renal excretion (approximately 20%). This dual clearance pathway differentiates bivalirudin from hirudin derivatives, which depend more heavily on renal elimination and carry longer half-lives of approximately 80 minutes.

Bivalirudin has been evaluated in multiple large randomized controlled trials spanning elective PCI, unstable angina, non-ST-elevation acute coronary syndromes (NSTEMI/ACS), and ST-elevation myocardial infarction (STEMI).

The Bivalirudin Angioplasty Trial (BAT) was the pivotal study for the original 2000 FDA approval. In this randomized trial of 4,312 patients undergoing PTCA for unstable angina or post-myocardial infarction ischemia, bivalirudin was compared with unfractionated heparin (UFH). Bivalirudin demonstrated lower rates of the combined endpoint of death, myocardial infarction, or abrupt vessel closure (6.2% vs 7.9%; p=0.039) and a substantial reduction in major in-hospital bleeding (3.5% vs 9.3%; p<0.001).

The REPLACE-2 (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events) trial enrolled 6,010 patients at 233 hospitals undergoing urgent or elective PCI and was published in JAMA in 2003 (Lincoff et al.). Patients received bivalirudin with provisional glycoprotein IIb/IIIa inhibitor (GPI) or UFH plus planned GPI. The primary composite endpoint of death, myocardial infarction, urgent revascularization, or in-hospital major bleeding was 9.2% with bivalirudin versus 10.0% with UFH plus GPI (p=0.32, meeting pre-specified non-inferiority criteria). Major bleeding was significantly reduced with bivalirudin (2.4% vs 4.1%; p<0.001), representing a 41% relative risk reduction.

ACUITY (Acute Catheterization and Urgent Intervention Triage strategy; Stone et al., NEJM 2006, doi:10.1056/NEJMoa062437) enrolled 13,819 moderate- to high-risk ACS patients. Bivalirudin alone suppressed ischemic events to a comparable extent as heparin plus GPI while significantly reducing major hemorrhagic complications (3.0% vs 5.7%; p<0.001).

HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction; Stone et al., NEJM 2008; PMID 18499566; doi:10.1056/NEJMoa0708191) randomized 3,602 STEMI patients undergoing primary PCI to bivalirudin or UFH plus GPI. At 30 days, bivalirudin significantly reduced major bleeding (4.9% vs 8.3%; relative risk 0.60; p<0.001) and net adverse clinical events (9.2% vs 12.1%; p=0.005). Cardiac mortality was lower with bivalirudin at 30 days (1.8% vs 2.9%; p=0.03). An increased rate of acute stent thrombosis within the first 24 hours was observed with bivalirudin (1.3% vs 0.3%); this excess risk attenuated by 30 days. Three-year follow-up maintained significant reductions in mortality, cardiac mortality, reinfarction, and major bleeding.

MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX; Valgimigli et al., NEJM 2015; doi:10.1056/NEJMoa1507854) enrolled 7,213 ACS patients and found no significant difference in the primary composite major adverse cardiovascular events endpoint between bivalirudin and UFH; however, all-cause mortality was lower with bivalirudin (1.7% vs 2.3%) and BARC 3 or 5 bleeding was reduced (1.4% vs 2.5%; relative risk 0.55).

A 2024 individual patient data meta-analysis published in Circulation comparing bivalirudin versus heparin in NSTEMI patients undergoing PCI confirmed that bivalirudin reduces serious bleeding (3.3% vs 5.5%) with comparable rates of mortality and ischemic events.

Typical dosage: 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours).

The following reflects the FDA-approved prescribing information for bivalirudin (Angiomax) and clinical trial protocols. All dosing is by intravenous administration only.

Standard PCI/PTCA dosing (including patients with HIT or HITTS): • IV bolus: 0.75 mg/kg administered immediately before the procedure • IV infusion: 1.75 mg/kg/h for the duration of the PCI procedure • Supplemental bolus: if activated clotting time (ACT) measured at 5 minutes is inadequate, an additional 0.3 mg/kg IV bolus may be given • Optional post-procedural infusion: 0.2 mg/kg/h may be continued for up to 4 hours following the procedure to reduce the risk of acute stent thrombosis; this may be further reduced to 0.1 mg/kg/h for an additional 14 to 20 hours if clinically indicated

Renal impairment dose adjustments: • Creatinine clearance (CrCl) 30 mL/min or greater: no change to bolus; infusion maintained at 1.75 mg/kg/h • CrCl less than 30 mL/min (not on dialysis): reduce infusion rate to 1.0 mg/kg/h; bolus dose unchanged • Hemodialysis-dependent patients: reduce infusion rate to 0.25 mg/kg/h; monitor ACT closely

Monitoring: • Measure ACT 5 minutes after initial bolus to confirm therapeutic anticoagulation • Monitor for bleeding signs and symptoms throughout and after the procedure • Assess renal function before and during administration

No routine dose adjustment is required based on sex, age alone, or hepatic impairment; however, elderly patients may have increased bleeding risk requiring clinical vigilance.

This information is provided for educational purposes only and does not constitute medical advice. Dosing decisions must be individualized by a licensed healthcare professional based on patient-specific factors including renal function, body weight, bleeding risk, and procedural complexity.

Bivalirudin is used as the primary anticoagulant during PCI and is routinely combined with oral antiplatelet agents rather than with other parenteral anticoagulants.

Standard dual antiplatelet background therapy: Bivalirudin is administered in the context of aspirin (typically 75 to 325 mg orally) and a P2Y12 receptor inhibitor (clopidogrel, ticagrelor, or prasugrel) as dual antiplatelet therapy. In HORIZONS-AMI, all enrolled patients received aspirin and clopidogrel as background therapy. Contemporary evidence suggests that potent P2Y12 inhibitors such as ticagrelor or prasugrel, in combination with bivalirudin, may mitigate the early acute stent thrombosis risk associated with bivalirudin monotherapy compared with clopidogrel.

Provisional glycoprotein IIb/IIIa inhibitors: The FDA label and major trials including REPLACE-2 and ACUITY support the provisional (bailout) use of a GPI alongside bivalirudin in select high-risk situations during PCI — for example, abrupt vessel closure, no-reflow phenomenon, or thrombus burden. Routine planned administration of GPI plus bivalirudin is not recommended due to additive bleeding risk without demonstrated benefit.

Use in heparin-induced thrombocytopenia: Bivalirudin is a preferred alternative anticoagulant in patients with confirmed or suspected HIT requiring PCI. The AT-BAT (Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia) trial provided evidence supporting this use. Bivalirudin eliminates heparin exposure entirely, avoiding the immune-mediated platelet activation characteristic of HIT.

Combinations to avoid: Co-administration with unfractionated heparin, low-molecular-weight heparin, warfarin, or thrombolytic agents substantially increases bleeding risk and should be avoided or requires heightened clinical monitoring. These combinations are not part of approved PCI regimens. Bivalirudin also has known physical incompatibilities with several IV medications and should not be mixed in the same IV line.

Bivalirudin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare)

Bleeding is the most clinically important adverse effect of bivalirudin and can occur at vascular access sites, the gastrointestinal tract, retroperitoneum, or intracranially. Across major randomized trials, bivalirudin consistently reduced major bleeding relative to heparin plus GPI. In REPLACE-2, major bleeding occurred in 2.4% of bivalirudin-treated patients versus 4.1% with UFH plus GPI (p<0.001). In HORIZONS-AMI, major bleeding rates were 4.9% versus 8.3% (p<0.001).

Acute stent thrombosis: A specific, time-sensitive safety concern identified in HORIZONS-AMI is an elevated rate of acute stent thrombosis occurring within the first 24 hours after PCI (1.3% bivalirudin vs 0.3% UFH plus GPI). The mechanism is thought to involve the rapid offset of thrombin inhibition before full platelet inhibition by clopidogrel is established. This risk was attenuated in subsequent trials using potent P2Y12 inhibitors (ticagrelor, prasugrel) and/or post-PCI bivalirudin infusion.

Other adverse effects reported in clinical trials and post-marketing include: • Back pain (observed frequently in early trials, often procedure-related) • Nausea • Headache • Hypotension • Bradycardia • Injection-site pain or reaction • Thrombocytopenia (rare, distinct from heparin-induced thrombocytopenia) • Hypersensitivity reactions including anaphylaxis (rare)

Contraindications: Active major bleeding and known hypersensitivity to bivalirudin or any component of the formulation.

Special populations: Patients with severe renal impairment (CrCl less than 30 mL/min) or on hemodialysis require dose reduction and ACT monitoring due to reduced drug clearance and prolonged anticoagulant exposure. Elderly patients may have higher baseline bleeding risk. Safety in pregnancy has not been established; bivalirudin should be used in pregnancy only when clearly necessary.

No antidote for bivalirudin exists. However, its short plasma half-life of approximately 25 minutes in patients with normal renal function means anticoagulant effects dissipate relatively rapidly upon discontinuation, which is an important management consideration in cases of bleeding. Bivalirudin is not efficiently removed by hemodialysis (approximately 25% removal). There is no current black-box warning in the prescribing information, though the label carries prominent warnings regarding bleeding risk and early acute stent thrombosis.